Sarepta Refuses FDA Request to Stop Shipping Muscular Dystrophy Drug Elevidys
The regulator had asked Sarepta Therapeutics to halt all shipments of its therapy, Elevidys, after three patients died from liver failure after taking it or a similar treatment.
.png?Expires=1838763821&Key-Pair-Id=K2ZIVPTIP2VGHC&Signature=IO0~CT3pU-TcxGc~yoZSmoQx23MZVuK-~4jSii~NKEblRmyO3el7NXPu~Rh1o23voASg7hlcHLw4kvQuDK1jssEhcjoNBBvEpZ~GGOAU6yosBhpHpeF179F~h7i6VxmsBNh9gtTutkoqY73O2YCFey~IAqSzKbBqETP1kP9cAg1916Z1YkJJs-5MliMrkZ5d7-mWGLbpHp2wGj2VlMph8XzYlL4~y1O7fB~JdIS~Rs4RMRs2x0WT1qUIpHAsf3GdwtOyAmKFSpIg8xCyNGZZ5h~13nXlmpd7uPvW8tBfttpG9pFTqcway-uch5WyfHOEfi7UlJCOWrr6fCYY5PMgSg__)
